Entera Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors surrounding Entera Bio’s promising developments in their oral GLP-2 and EB613 programs. The company has presented encouraging preclinical data for their oral GLP-2 analog, developed in collaboration with OPKO Health, which could offer significant advantages over existing therapies for Short Bowel Syndrome. This oral candidate could potentially provide greater convenience and better compliance for patients compared to the current treatment, Gattex, which requires daily injections.
Additionally, Entera Bio’s EB613, an oral anabolic tablet for osteoporosis, has shown positive results in increasing bone mineral density and improving bone strength in clinical studies. The data presented at a recent conference demonstrated significant improvements in bone parameters, suggesting that EB613 could rapidly enhance bone health and fracture resistance. These promising developments in Entera Bio’s pipeline contribute to the positive outlook and the Buy rating assigned by Selvaraju.